Dr. Reddy's Laboratories LimitedRDYNYSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +15.85% | +20.09% | +11.37% | +9.84% | +4.41% |
| Gross Profit Growth | +16.23% | +13.93% | +4.93% | +0.78% | -4.58% |
| EBITDA Growth | +8.29% | +24.32% | +13.26% | +1.71% | -19.44% |
| Operating Income Growth | +8.41% | +17.97% | -2.51% | -0.22% | -23.94% |
| Net Income Growth | +2.49% | +21.94% | +1.85% | +14.49% | -14.40% |
| EPS Growth | +2.42% | +21.85% | +2.10% | +14.67% | -14.33% |
| EPS Diluted Growth | +2.42% | +21.89% | +1.98% | +14.62% | -14.29% |
| Weighted Average Shares Growth | +0.09% | +0.09% | -0.23% | -0.19% | -0.01% |
| Weighted Average Shares Diluted Growth | +0.05% | +0.04% | -0.11% | -0.13% | -0.13% |
| Dividends per Share Growth | -100.00% | -100.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +12354.31% | +16050.72% | +72.19% | +67.16% | +64.77% |
| Free Cash Flow Growth | -30998.76% | +14645.50% | +116.31% | +286.50% | +0.00% |
| Receivables Growth | +10848.98% | +15.16% | +42.37% | +17.50% | +11.46% |
| Inventory Growth | +9704.26% | +11.85% | +10.26% | +5.25% | +10.30% |
| Asset Growth | +10636.65% | +27.22% | +25.10% | +16.32% | +17.01% |
| Book Value per Share Growth | +9761.90% | +18.73% | +19.08% | +17.63% | +17.22% |
| Debt Growth | +21314.41% | +133.60% | +58.58% | +20.60% | +32.59% |
| R&D Expense Growth | +19.64% | +5.54% | +0.82% | -14.70% | -7.64% |
| SG&A Expenses Growth | +19.23% | +17.48% | +2.16% | +14.90% | +11.61% |